Fig. 5

Effects of prediction-matched treatments on clinical outcome in canine osteosarcoma patients treated with doxorubicin and/or carboplatin. a Survival analysis of 15 COS33 dogs receiving doxorubicin/carboplatin combination treatment separated into four prediction groups based on the best performing doxorubicin and carboplatin models. Significant differences in curves determined by Log Rank trend test. b Survival analysis between COS33 dogs (n = 32) that were treated with a drug our best performing models predicted them to be sensitive to (“COXEN matched”) and dogs that were not (“COXEN mismatched”). For dogs that received combination treatment, a sensitive prediction on either the doxorubicin or carboplatin model was needed to be a COXEN match. Significant difference in disease free interval between the curves was determined by Log Rank test